Advances In Dna Sequence-specific Agents

Other | September 1, 2002

byChapman, B.J., B.j. Chapman

not yet rated|write a review
This series encompasses design, synthesis, application, and analytical methods (including clinical and in vitro) for the study of these critical interactions. As our understanding of the genome and proteome expands, general developments in the field of DNA sequence specific interaction are likely to play an increasingly important role. Accordingly, manuscripts have been solicited from experts covering a diverse range of fields, reflecting the cross-disciplinary and dynamic nature of the series.


Volume 4 describes work on the modification of DNA by AT specific anticancer drugs, DNA alkylation events which involve metabolite generation, DNA sequence recognition by two selective binders, bulged DNA microenvironments as molecular targets, DNA sequence specific binding by short peptides and the analysis of DNA-protein interactions using DNase I footprinting methodology.


Features include:
• Expert contributors from the Biomedical world
• Emerging areas of drug design and therapeutic applications
• Nucleic acid-protein interactions
• Color graphics of molecular modeling analyses
• New and emerging methodologies

Pricing and Purchase Info

$128.39 online
$166.67 list price (save 22%)
In stock online
Ships free on orders over $25

From the Publisher

This series encompasses design, synthesis, application, and analytical methods (including clinical and in vitro) for the study of these critical interactions. As our understanding of the genome and proteome expands, general developments in the field of DNA sequence specific interaction are likely to play an increasingly important role...

Format:OtherDimensions:162 pages, 1 × 1 × 1 inPublished:September 1, 2002Publisher:Elsevier ScienceLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:0080526136

ISBN - 13:9780080526133

Customer Reviews of Advances In Dna Sequence-specific Agents

Reviews

Extra Content

Table of Contents

1. Preferential damage to defined regions of genomic DNA by AT-specific anticancer drugs (J.M. Woynarowski).
2. DNA-alkylating events associated nitrogen mustard based anticancer drugs and the metabolic byproduct acrolein (M.E. Colvin, J.N. Quong).
3. Molecular basis for recognition and binding of specific DNA sequences by calicheamicin and duocarmycin (G. Bifulco,et al.).
4. Enediyne antibiotic neocarzinostatin as a radical-bsed probe of bulged structures in nucleic acids (Zhen Xi, I.H. Goldberg).
5. Sequence-specific DNA binding by short peptides (T. Morii, K. Makino).
6. Equilibrium and kinetic quantitative DNAse I footprinting (G.M. Dhavan, A.K.M.M. Mollah, M. Brenowitz).